--- title: 'Clinical Daily Summary: What Happened on October 24, 2026' headline: Enhertu fails as neoadjuvant treatment in early breast cancer description: Five-year melanoma data favor relatlimab plus nivolumab. In an exploratory bladder cancer study, visugromab added to nivolumab produced more responses than nivolumab plus placebo. url: https://thebench.bio/news/clinical/2026-10-24 topic: clinical date: '2026-10-24' covers: - '2026-10-24' date_published: '2026-10-24T12:01:13Z' date_modified: '2026-10-24T12:01:13Z' tags: - Clinical - Industry sources: 3 publisher: TheBench.Bio --- # Clinical Daily Summary: What Happened on October 24, 2026 **Enhertu fails as neoadjuvant treatment in early breast cancer** Five-year melanoma data favor relatlimab plus nivolumab. In an exploratory bladder cancer study, visugromab added to nivolumab produced more responses than nivolumab plus placebo. ## Today in brief Enhertu failed as a neoadjuvant treatment for early breast cancer. [1] A five-year analysis in advanced melanoma found continued benefit from relatlimab plus nivolumab over nivolumab alone. [2] In an exploratory bladder cancer study, more patients had complete pathologic responses with visugromab plus nivolumab than with nivolumab plus placebo. [3] ## Five-year melanoma analysis finds continued survival benefit After at least 57.3 months of follow-up, relatlimab plus nivolumab continued to improve progression-free, overall and melanoma-specific survival over nivolumab alone in a prespecified analysis. [2] The trial enrolled 714 patients with advanced melanoma. [2] Hazard ratios favored the combination for progression-free survival, overall survival and melanoma-specific survival: 0.77, 0.78 and 0.71, respectively. [2] The safety profile remained consistent with earlier reports. [2] Among patients whose tumors had at least 1% PD-L1 expression, higher levels of LAG-3-positive CD8 cells were associated with worse outcomes on nivolumab alone. [2] Primary resistance was less prevalent with added relatlimab than with nivolumab alone. [2] The authors said the findings support the possibility that relatlimab can overcome resistance to nivolumab mediated by LAG-3. [2] ## Visugromab combination shows higher response rates in exploratory bladder study Complete pathologic responses occurred in 5 of 15 evaluable patients given visugromab plus nivolumab, compared with 1 of 13 given nivolumab plus placebo in GDFATHER-NEO. [3] The exploratory Phase 2a study enrolled 31 patients with newly diagnosed muscle-invasive bladder cancer who were unable or unwilling to receive cisplatin. [3] Major pathologic response rates were 60% with visugromab and 23% with placebo. Radiographic response rates were 60% and 15%, respectively. [3] Participants received three treatment cycles in a sequentially assigned, nonrandomized study. [3] Grade 3 or 4 treatment-related adverse events affected 13% of the combination group and 20% of the placebo group. [3] There were no treatment-related discontinuations or surgery delays. [3] The authors said the results support further assessment of visugromab in muscle-invasive bladder cancer. [3] ## The day in numbers - **0.78**: Overall-survival hazard ratio for relatlimab plus nivolumab versus nivolumab alone in the five-year melanoma analysis. [2] - **5 of 15 vs. 1 of 13**: Complete pathologic responses with visugromab plus nivolumab versus nivolumab plus placebo among evaluable bladder cancer patients. [3] ## Also published - [ESMO26: Zai and Ideaya showcase DLL3 drugs in lung cancer](), pharmaphorum - [Weekly reads: Trump’s Granddaughter gets MUSE cell injection, fibroblast plasticity, unusual FDA warning](), The Niche ## Sources 1. [ESMO26: Neoadjuvant Enhertu fails in early breast cancer](), pharmaphorum, 2026-10-24 2. [Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial](), Nature Medicine, 2026-10-24 3. [Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial](), Nature Medicine, 2026-10-24 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: